BCYC
Bicycle TherapeuticsBCYC
BCYC
About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Employees: 305
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
0.62% less ownership
Funds ownership: 88.1% [Q4 2024] → 87.48% (-0.62%) [Q1 2025]
7% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 30
2% less funds holding
Funds holding: 97 [Q4 2024] → 95 (-2) [Q1 2025]
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
40% less capital invested
Capital invested by funds: $586M [Q4 2024] → $354M (-$232M) [Q1 2025]
69% less call options, than puts
Call options by funds: $84K | Put options by funds: $269K
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
67%
upside
Avg. target
$22
157%
upside
High target
$32
282%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Morgan Stanley Jeffrey Hung | 103%upside $17 | Equal-Weight Maintained | 6 May 2025 |
RBC Capital Gregory Renza | 282%upside $32 | Outperform Maintained | 2 May 2025 |
B. Riley Securities Kalpit Patel | 67%upside $14 | Neutral Maintained | 2 May 2025 |
JMP Securities Reni Benjamin | 163%upside $22 | Market Outperform Maintained | 2 May 2025 |
Needham Ami Fadia | 246%upside $29 | Buy Reiterated | 2 May 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 57,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i.
Neutral
Business Wire
3 weeks ago
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025. “In the first quarter, we continued to advance our business priorities and our pipeline of oncology therapeutics. We were pleased to share additional human im.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®).
Neutral
Seeking Alpha
1 month ago
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's we.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments. Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chairman of the Bicycle Therapeutics Board of Directors as Mr. Legault and Richard Kender, MBA, will retire f.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Charts implemented using Lightweight Charts™